Mead Johnson Eyes China’s One-Child Policy, Hong Kong Formula Rule
This article was originally published in The Tan Sheet
Executive Summary
The one-child policy in much of China stifles Mead Johnson’s annual formula volume growth there, says incoming CEO Kasper Jakobsen. Formula sales there could be slowed with Hong Kong limiting the amount that consumers can take out of the territory.
You may also be interested in...
People In Brief
Jakobsen next in line as Mead Johnson CEO; Blake takes over Bayer U.S. from Babe; Himmel ends brief tenure as ChromaDex CEO; Capitol Hill veteran O’Donnell joins NACDS; Merz makes Hartman derma VP; USANA strengthens scientist roster; more People In Brief.
Nestle Pays Nearly $12 Bil. For Desirable Pfizer Nutrition Portfolio
Nestle’s $11.85 billion acquisition of Pfizer’s pediatric nutritionals business came in above or at the upper end of most analysts’ expectations. With the deal, Nestle keeps the portfolio – projected to generate $2.4 billion in 2012 sales – away from rivals Danone and Mead Johnson.
Abbott's ‘Bedrock Of Good Health’ Nutritionals Business Faces Mounting Infant Formula Litigation
Nutritional product business had 5.1% Q1 sales growth and is like Abbott’s other segments, “super well-aligned to the global demographics and trends in health care,” says CEO Ford. But as it defends complaints of damages from powder formulas made at facility found with unsafe levels of bacterial contaminants, Abbott’s also targeted in litigation alleging failure to warn about risk of infants born prematurely developing necrotizing enterocolitis if fed cow’s milk-based formula.